<DOC>
	<DOCNO>NCT01580020</DOCNO>
	<brief_summary>The study intend characterize clinical benefit regard safety efficacy long term treatment Lucentis comparison Ozurdex additional 6 month 3-month follow-up period , follow initial 6-month treatment respective core study CRFB002EDE17 ( NCT01396057 ) CRFB002EDE18 ( NCT01396083 ) .</brief_summary>
	<brief_title>Extension Study Compare Long-term Efficacy Safety Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant Patients With RVO</brief_title>
	<detailed_description />
	<mesh_term>Retinal Vein Occlusion</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Patients must complete core study assessment month 6 study CRFB002EDE17 CRFB002EDE18 , respectively Patients experience uncontrollable rise IOP core study CRFB002EDE17 respectively CRFB002EDE18 , i.e . IOP could decrease stable level &lt; 25mmHg . Use investigational drug Current use likely need systemic medication know toxic lens , retina optic nerve History hypersensitivity Ranibizumab Ozurdex component ranibizumab respectively Ozurdey formulation Any type advance , severe unstable disease treatment , could interfere evaluation put patient special risk Women pregnant breast feeding ( pregnancy define state female conception termination gestation , confirm positive hCG laboratory test ( &gt; 5 mIU/mL ) menstruating capable become pregnant* practice medically approve method contraception ( Pearl Index &lt; 1** ) *** least 4 week end treatment . A negative pregnancy test ( serum ) woman girls enter menarche require sufficient lead time randomization definition postmenopausal : 12 month natural ( spontaneous ) amenorrhea 6 month spontaneous amenorrhea serum FSH level &gt; 40 mIU/mL 6 week post surgical bilateral oophorectomy without hysterectomy example particularly reliable method Pearl Index ( PI ) &lt; 1 , accord guideline `` Deutsche Gesellschaft für Gynäkologie und Geburtshilfe '' : Combination pill estrogen gestagen ( minipill , PI=0.10.9 ) Vaginal ring ( NuvaRing® , PI=0.65 uncorr . ; 0.4 corr . ) Contraceptive patch ( EVRA® , PI= 0.72 uncorr . ; 0.9 corr . ) Estrogenfree ovulation inhibitor ( Cerazette® , PI=0.14 ) Progestincontaining contraceptive ( Implanon® , PI=00.08 ) Injectable 3month depot progestin ( PI=0.31.4 ; 0.88 corr . ) Intrauterine progestin device ( Mirena® , PI=0.16 )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Macular Degeneration</keyword>
	<keyword>Macular Edema</keyword>
	<keyword>Retinal Vein Occlusion</keyword>
	<keyword>Choroidal Neovascularization</keyword>
	<keyword>Signs Symptoms</keyword>
	<keyword>Retinal Degeneration</keyword>
	<keyword>Retinal Diseases</keyword>
	<keyword>Eye Diseases</keyword>
	<keyword>Venous Thrombosis Sensation Disorders</keyword>
	<keyword>Dexamethasone acetate</keyword>
	<keyword>Dexamethasone</keyword>
	<keyword>Dexamethasone 21-phosphate</keyword>
	<keyword>BB 1101</keyword>
	<keyword>Anti-Inflammatory Agents</keyword>
	<keyword>Therapeutic Uses</keyword>
	<keyword>Vision , Low</keyword>
	<keyword>Signs</keyword>
	<keyword>Vision Disorders</keyword>
</DOC>